Nuveen’s Eterna Therapeutics ERNA Stock Holding History

Nuveen’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14	Closed	-$214K	–	3324
2022 Q1	$214K	Hold	14	–	–	﹤0.01%	3179
2021 Q4	$485K	Hold	14	–	–	﹤0.01%	3079
2021 Q3	$1.24M	Sell	14 -23	-62%	-$1.99M	﹤0.01%	2906
2021 Q2	$4.96M	Buy	+37	New	+$5.33M	﹤0.01%	2250

Other funds holding ERNA

CPWM

Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return

Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen's ERNA Position: Q2 2022 in Review

Nuveen sold out of Eterna Therapeutics (ERNA) in Q2 2022, closing a stake of 14 shares — an estimated $214K sold.

Nuveen first reported a position in ERNA in Q2 2021 and held it in 4 quarters. The position peaked at $4.96M in Q2 2021. 34 funds tracked by Wall St. Rank hold ERNA as of Q2 2022.

Nuveen reported no remaining Eterna Therapeutics position as of Q2 2022 after selling out during the quarter.
Nuveen sold 14 Eterna Therapeutics shares in Q2 2022, an estimated $214K.
Nuveen first reported a position in Eterna Therapeutics in Q2 2021 and held it in 4 quarters.
Nuveen's Eterna Therapeutics position peaked at $4.96M in Q2 2021.
34 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.